COVID-19 vaccine updates from Nook and Corner

  • February 21, 2021 05:19 PM AEDT
  • Team Kalkine
    Team Kalkine
    admin Team Kalkine
    16942 Posts

    Team Kalkine comprises of experts who understand various markets nuances and are enthusiastic and passionate to provide best possible offerings in the form of insights and stories. The team has rich experience of working across different markets with...

COVID-19 vaccine updates from Nook and Corner

Summary

  • With more than 200 million doses distributed worldwide, researchers are still concerned that it will likely take years for most of the world’s people to become immunised.
  • Russia has authorised its 3rd COVID-19 vaccine for domestic use.
  • India becomes the second fastest country in the world to cross the milestone of 10 million vaccination, after the US.
  • G7 countries promise to increase vaccine supply to the developing nations.

The pressure is on for nations to vaccinate people against COVID-19, especially when the new strain is also picking the pace. As per media reports, close to 200 million people have been vaccinated, covering more than 85 countries. With the launch of several vaccines and the commencement of vaccination drives, researchers are still concerned that it will likely take years for most of the world’s people to become immunised against COVID-19.

On the one hand, when every nation is trying hard to increase the number of people receiving a dose of COVID-19 vaccine, Oxford and AstraZeneca are preparing to adapt their COVID-19 vaccine to protect against new strains. 

Many countries have started a vaccination drive successfully, while some are getting ready to start in the next few weeks. Besides, a few of the world's richest countries are pledging to share COVID-19 vaccines with developing and poor nations.

With this backdrop, let us acquaint you with the latest COVID-19 vaccination updates-

Russians get 3rd COVID-19 vaccine

On 20 February 2021, Russia has authorised its 3rd COVID-19 vaccine for domestic use. The vaccine is manufactured by the Chumakov Centre and labelled as CoviVac.

Source: Copyright © 2020 Kalkine Media Pty Ltd.

 

According to some media sources, Russian has followed the same approach for approving CoviVac as it did for earlier 2 COVID-19 vaccines, authorised without performing late-stage clinical trials. Inoculations will start after the trails are conducted and proved to be successful. Russia already authorised two COVID-19 vaccines are, Sputnik V and EpiVacCorona.

India attained 10 million vaccination mark in 34 days

India took 34 days to obtain the landmark feat of 10 million COVID-19 vaccinations and becomes the second-fastest in the world to cross this milestone after the US.  The US took 31 days, while the UK took 56 days to beat this vaccination mark.

Source: Copyright © 2020 Kalkine Media Pty Ltd.

 

India took 34 days to obtain the landmark feat of 10 million COVID-19 vaccinations and became the second-fastest globally to cross this milestone after the US. Besides, more than 6 lakh healthcare workers have received the second dose.

DO READ: A race against COVID-19: Meet five global vaccine developers in the fray

Australia Vaccine update

The first Pfizer vaccine dose has reached Brisbane today morning and now will be dispatched for Gold Coast. Prime Minister Scott Morrison and Paul Kelly, Chief Medical Officer, along with few more health workers and aged residents, are among the first batch to receive the dose.

Longer dose gap between Oxford-AstraZeneca’s vaccine shots more effective

A Lancet study reported that the vaccine manufactured by AstraZeneca Plc (LON:AZN) and Oxford University would be more effective when two doses are given at an interval of three-months rather than the present gap of six weeks.  

The study has estimated that the single dose of the vaccine gives up to 76% protection for a period of three months.

Source: © Rawf88 | Megapixl.com

 

The study also suggested that it would also help governments vaccinate a larger number of people in a shorter interval of time.

The researchers stated that this dosage regimen is helpful, while COVID-19 vaccine supplies are initially limited and could allow nations to immunise the larger population promptly.

 

Vaccine Distribution in Japan

The Japanese government has signed a contract with AstraZeneca to produce the vaccine for 60 million people. The production for local distribution will start as soon as health ministry approval is received.

Britain to vaccinate adults by July end

Prime Minister Boris Johnson stated that all adults will be administered the first shot of a COVID-19 vaccine in Britain by July end.  Britain now intends to give the first dose to all aged people (more than 50 years) by 15 April 2021.

Vaccine manufactured by Pfizer Inc/BioNTech SE and developed by the AstraZeneca/Oxford University is being rolled out in the UK.

G7 Leaders Commitment to increase Vaccine supply

Over a call that lasted for more than 45 minutes, the G7 leaders have committed their increased support to WHO led Covax global vaccine drive. The countries agreed to increase the supply of surplus vaccines to the developing nations. In his first international meeting, the US President, Joe Biden, promised an extra USD 4 billion support to the Covax scheme.

The distribution plans supporting anti-poverty campaigns on how many doses and when will they be sent will be taken later this year depending upon any additional shots needed during autumn and keeping into account the supply chain.

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK